Bronchogen: Lung Bioregulator Research and Measurements

Bronchogen: lung bioregulator research and what it measured

Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL), a synthetic lung bioregulator from the Khavinson series studied for its action on bronchial epithelium. This guide covers what a lung bioregulator is, how Bronchogen differs from Chonluten, what the research shows, dose notes, storage, and where to find Bronchogen for sale as a research-use vial, nasal spray or preloaded pen.

Bronchogen as a lung bioregulator

Bronchogen is a lung bioregulator: a short synthetic peptide, Ala-Glu-Asp-Leu, that the Khavinson series assigns to lung tissue and the bronchial mucosa, where it is studied for its effect on the epithelial cells lining the airways. The term comes from the peptide bioregulation model developed in St. Petersburg, in which each organ is paired with a short peptide thought to act on that tissue's gene expression.

Chonluten is the other respiratory bioregulator in the series, and the two are easy to confuse. Bronchogen is a tetrapeptide (four amino acids) whose literature centers on regeneration of bronchial epithelium and lung tissue. Chonluten is a tripeptide, Glu-Asp-Gly, assigned to the bronchial mucosa and studied more for airway inflammation and mucosal support, with a further line of work on endurance. Both are synthetic cytogens, both are sold as research-use vials, nasal sprays and preloaded pens, and neither is an approved medicine. The Chonluten guide covers the tripeptide in detail.

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Published November 8, 2025 · Updated July 5, 2026 · ~12 min read

What is Bronchogen peptide?

So, the bronchogen peptide — what is it, exactly? Bronchogen (sometimes misspelled "broncogen") is a specialized peptide bioregulator and bioregulatory peptide formulated to target, support, and regenerate the tissues of the lungs and the bronchial mucosal lining. It belongs to a class of compounds known as synthesized short peptides for the lungs, and it is tissue-specific: it is intended to act on the respiratory tract rather than the whole body.

In scientific terms, the tetrapeptide Bronchogen is an artificially synthesized short-chain geroprotective peptide consisting of four amino acids — Alanine, Aspartic acid, Glutamic acid, and Leucine (Ala-Glu-Asp-Leu, or AEDL). Because it has a low molecular weight, it is proposed to pass through the digestive system via oral administration, enter the bloodstream, and reach the cells of the respiratory tissues. As a bronchogen khavinson peptide, it shares the research lineage of other Khavinson bioregulators such as Chonluten, Vesugen, and Cardiogen.

Form and Labeling

Bronchogen is most often supplied as bronchogen peptide capsules, frequently labeled as a "Bronchogen 20mg" peptide complex. It is not an approved medicine in the United States, and PrymaLab supplies it for laboratory research use only. Check the current legal status in your own region.

Because search phrasings vary, you may also find this compound under queries such as "bronchogen peptide what is it," "what is bronchogen peptide used for," "bronchogen peptide khavinson," "bronchogen peptide bioregulator lungs," "bronchogen peptide bioregulator bronchial," and "bronchogen peptide lung bioregulator." Each refers to the same Ala-Glu-Asp-Leu respiratory bioregulator described here, aimed at optimizing respiratory health and overall lung health.

How does the Bronchogen peptide work?

If you are wondering how lung bioregulators work, the answer lies in tissue specificity and epigenetic regulation. The amino-acid sequence of the bronchogen peptide bioregulator is proposed to be keyed to the respiratory system, so that it interacts mainly with the cells of the lungs, bronchial tubes, and respiratory mucosa. In the Khavinson model, the bronchogen peptide bioregulator for the lungs is proposed to work on bronchial epithelial cells in stages:

1. Cellular penetration: the small four-amino-acid molecule crosses into respiratory cells and reaches the nucleus.
2. DNA binding: it seeks out a specific promoter region on the DNA.
3. Gene activation: binding is proposed to make that gene accessible for transcription, potentially influencing markers like NKX2-1, interacting with specific transcription factors like FOXA1 to modulate gene expression.
4. Protein synthesis: the cell transcribes and translates the structural proteins the lung tissue needs, such as surfactant protein B, to maintain healthy surfactant production and regulate alveolar surface tension.
5. Cellular restoration: with fresh proteins, the cell can repair damage, facilitating cellular regeneration and broader tissue regeneration to function more like a younger cell.

Bronchial Mucosa Repair and Local Immunity

A key proposed action of the bronchogen peptide bioregulator for the bronchial lining is supporting the bronchial epithelium, specifically the ciliated cells and club cells that sweep debris out of the lungs and addressing goblet cell hyperplasia or squamous metaplasia to manage protective MUC5AC mucus production. By supporting this lining and modulating the local inflammatory response and immune response, including the production of secretory immunoglobulin A, Bronchogen is proposed to help restore the lungs' self-cleaning mechanism and improve mucociliary clearance. It is also discussed in the context of local immunity — supporting secretory IgA, CXCL12, NKX2-1, SCGB3A2, and SCGB1A1 expression in the BALF, and healthy alveolar macrophage signaling. These are mechanistic, largely preclinical observations involving the analysis of bronchoalveolar lavage fluid, not proven human outcomes.

Bronchogen peptide benefits in the research literature

Because it is proposed to operate at the level of cellular repair, the reported bronchogen benefits cascade into broader pulmonary function, respiratory capacity, and respiratory health. The primary bronchogen peptide benefits discussed in bioregulator literature include:

• Supporting age-related lung decline: proposed to support elastin, collagen, and surfactant production in the lung matrix, helping maintain elasticity.
• Improving lung capacity after illness: studied for accelerating repair of microscopic lesions and reversing squamous metaplasia after respiratory infections.
• Bronchial support in smokers and ex-smokers: proposed to support regeneration of the bronchial lining damaged by smoke and reverse signs of squamous metaplasia.
• Airway hyper-reactivity: discussed in bioregulator literature, with no controlled study and no asthma endpoint.
• Environmental exposure: proposed in the same literature, without supporting measurements.

The honest limitation: there are no large independent randomized human trials establishing efficacy for the bronchogen peptide. It cannot regrow destroyed alveoli and will not "cure" chronic obstructive lung pathology like COPD; frame it as quality-of-life support, and treat overnight-cure claims as marketing.

Measured findings: bronchial cultures and DNA melting

Two Bronchogen papers report measurements rather than models. In 2012 Khavinson, Linkova, Polyakova and colleagues looked at the differentiation factors CXCL12 and Hoxa3 in cultures of human embryonic pancreatic and bronchial cells, and CXCL12 and WEGC1 in human prostatic fibroblasts (Khavinson et al. 2012). Expression of these factors fell in late-passage, aging cultures. Bronchogen (Ala-Glu-Asp-Leu) stimulated them in bronchial epithelial cells, while pancragen did so in pancreatic cells and vesugen in fibroblasts, and the effect was more pronounced in the aged cultures (Khavinson et al. 2012).

The second paper, by Monaselidze, Khavinson and colleagues in 2011, measured DNA melting by differential scanning microcalorimetry (Monaselidze et al. 2011). Bronchogen raised the melting temperature of calf thymus and mouse liver DNA by 3.1 °C within a narrow range of molar ratios (0.01 to 0.055 peptide per base pair), with no further rise at higher ratios and no change in melting enthalpy. The authors concluded that the peptide stabilises DNA, binds both strands mainly at the bases and is neither AT- nor GC-specific (Monaselidze et al. 2011). That paper's title gives the sequence as Ala-Asp-Glu-Leu, while other papers from the group write Ala-Glu-Asp-Leu (Khavinson et al. 2012) (Khavinson et al. 2016). The two orders have the same composition and mass, so a reader comparing studies should check which one was used.

A separate docking study predicted that AEDL binds the DNA sequence ctcc (Khavinson et al. 2016), but that is a computed model, not a measurement.

Bronchogen vs Taxorest: synthesized vs natural

Bronchogen (a synthesized "cytogen") is often compared with Taxorest, a natural lung extract ("cytomax"). Synthesized peptides are exact copies of the active molecule and act faster; natural extracts act more slowly but may nourish tissue longer. The bioregulator literature pairs the two, with Bronchogen as the defined peptide and Taxorest as the tissue extract.

Bronchogen handling in the lab

Bronchogen is not an approved medicine and no human dose has been established. The figures that circulate for capsule courses come from supplier and bioregulator literature, not from a published trial, and this page does not repeat them.

1. Formats — oral capsules containing lyophilized powder (often a Bronchogen 20mg peptide complex), and lyophilized vials for laboratory work.
2. Dissolving a vial — a lyophilized peptide is dissolved in a suitable diluent; the concentration is the mass of peptide divided by the volume added.
3. Storage — lyophilized powder cold and out of the light; solutions refrigerated.
4. Records — note the lot number, the diluent and the concentration alongside any result.

Bronchogen combinations studied with other bioregulators

In the Khavinson framework, organs do not work in isolation, so Bronchogen is often "stacked" with other tissue bioregulators or systemic repair peptides like BPC-157 and GHK-Cu:

• Respiratory-immune (Bronchogen + Vladonix): pairs lung repair with thymus/immune support to guard against secondary infection.
• Cardiopulmonary (Bronchogen + Ventfort): adds vascular support for the pulmonary capillaries to enhance respiratory capacity — of interest to athletes targeting VO2 max.
• Mucosal repair (Bronchogen + Stamakort): addresses silent acid reflux that can irritate the bronchial tubes by also supporting the gastric lining.

These pairings come from bioregulator literature and practitioner material, not from controlled studies of the combinations.

Safety and side effects in the literature

Reports from its originating research tradition describe a favorable safety profile: as a short peptide of natural amino acids, Bronchogen is said to be well tolerated, with no documented dependency or overdose risk because excess is metabolized. Reported bronchogen peptide side effects are uncommon and mild — occasionally short-lived gastrointestinal upset when first starting. Independent, large-scale human trial data remain limited, so read these reports as encouraging rather than definitive.

Precautions: avoid during pregnancy or breastfeeding unless a physician advises otherwise; use pediatric dosing only under medical supervision; and check the capsule's inactive ingredients (gelatin or cellulose shell, fillers) for personal allergies.

Where to find Bronchogen for sale

As peptide therapy grows, so does the number of vendors. Finding legitimate bronchogen for sale requires diligence — read bronchogen peptide reviews, but buy on documentation rather than hype. Use the checklist below.

PrymaLab's bioregulator catalog is a reference point for the transparency standards a supplier should meet.

Frequently asked questions

What is Bronchogen peptide and what is it used for?

Bronchogen is a synthesized short-chain peptide bioregulator (the tetrapeptide Ala-Glu-Asp-Leu) designed to support and regenerate lung and bronchial tissue. It is used mainly to support recovery after respiratory illness, age-related lung decline, and bronchial health in smokers. In the Khavinson model it acts epigenetically, potentially influencing factors like FOXA2, to drive repair-related protein synthesis.

What are the main Bronchogen peptide benefits?

Reported bronchogen peptide benefits include supporting lung elasticity with age, improving lung capacity after illness, aiding bronchial repair in smokers, easing airway hyper-reactivity over time, and helping the lungs clear pollutants. Evidence is largely preclinical and from its originating research school, so strong disease claims should be treated cautiously.

What did the Bronchogen studies measure?

The primary measurements are in cell culture: a 2012 study of differentiation factors in human bronchial epithelial cultures, where Bronchogen stimulated CXCL12 and Hoxa3 more strongly in aged cultures, and a 2011 differential scanning microcalorimetry study, where it raised the melting temperature of DNA. No human dose has been established, and the capsule courses quoted by suppliers are not from a trial.

Has Bronchogen been studied in asthma?

No. Bronchogen is not an approved medicine and is not an acute rescue medication. The published work is cell culture and DNA binding; there is no controlled study with an asthma or COPD endpoint, so the airway claims that circulate for it are not supported by the literature.

Are there Bronchogen peptide side effects?

Reported bronchogen peptide side effects are uncommon and mild, most often brief gastrointestinal upset when first starting. Its originating research tradition reports no dependency or overdose risk because excess peptide is metabolized. Controlled human trial data are limited, and there are no safety data in pregnancy, nursing or children.

Where can I find Bronchogen for sale, and do I need a prescription?

Bronchogen is sold as a research chemical, not as an approved medicine or a supplement, and PrymaLab supplies it for laboratory research use only. Local rules vary. Look for bronchogen for sale from suppliers who state the Ala-Glu-Asp-Leu composition, issue a certificate that matches the lot number on the vial and can be verified, and avoid cure-all claims or suspiciously low prices.

Is Bronchogen a Khavinson peptide?

Yes. The bronchogen khavinson peptide comes from the bioregulator research tradition associated with Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, which developed short, tissue-specific peptides — including synthesized respiratory peptides — to support organ-specific repair.

References and further reading